TipRanks on MSN5h
BioNTech initiated with a Buy at BerenbergBerenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize ...
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target remains the same with $150.00. Don't Miss our ...
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus and ...
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00. Don't Miss our Black Friday Offers: Robert Burns has given ...
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
BioNTech (NASDAQ:BNTX) stock rose 1.9% after Evercore ISI upgraded its stance on the drugmaker to ‘outperform’ from ‘in line’ ...
GlobalData on MSN5d
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback